- Poster presentation
- Open Access
Effects of levosimendan in acute heart failure, cardiogenic and septic shock
© BioMed Central Ltd 2008
- Published: 13 March 2008
- Public Health
- Observational Study
- Cardiac Output
Levosimendan, a calcium sensitizer, improves cardiac output in patients with acute decompensated heart failure (ADHF). Its effect in patients with cardiogenic and septic shock remains unknown. We hypothesized that levosimendan improves cardiac output similarly in patients with ADHF (group A), cardiogenic (group C), and septic shock (group S).
Sixty consecutive patients were enrolled in this prospective observational study. Levosimendan infusion was started in all patients at 0.05 μg/kg/min intravenously, without a bolus dose, and was increased by 0.05 μg/kg/min every 30 minutes to a maximum of 0.2 μg/kg/min intravenously, at which time levosimendan infusion was continued for 24 hours. The thermodilution cardiac output and central venous saturation (ScvO2) were measured at baseline and every 4 hours thereafter for a total of 48 hours. Hypotension (mean arterial pressure < 65 mmHg) was treated with norepinephrine, titrated to mean arterial pressure ≥ 65 mmHg.
Levosimendan has similar hemodynamic effects when administered to patients with ADHF, cardiogenic, and septic shock. It did not appear to have a significant effect on ScvO2.
This article is published under license to BioMed Central Ltd.